Safety of Japanese encephalitis live attenuated vaccination in post-marketing surveillance in Guangdong, China, 2005–2012

• DOI: 10.1016/j.vaccine.2013.11.107
• Publication Date: 2014-02-04T05:31:48Z
• Authors: Yu Liu; Hualiang Lin; Qi Zhu; Chenggang Wu; Zhanjie Zhao; Huizhen Zheng
• Keywords: Male; China; Japanese Encephalitis Vaccines; Infant; Vaccines, Attenuated; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Child, Preschool; Product Surveillance, Postmarketing; Adverse Drug Reaction Reporting Systems; Humans; Female; Child; Encephalitis, Japanese

We reviewed the adverse events following immunization of live attenuated Japanese encephalitis vaccine in Guangdong Province, China. During the period of 2005-2012, 23 million doses of live attenuated Japanese encephalitis vaccine were used and 1426 adverse events were reported (61.24 per million doses); of which, 570 (40%) were classified as allergic reactions (24.48 per million doses), 31 (2%) were neurologic events (1.33 per million doses), and 36 (2.5%) were diagnosed as serious adverse events (1.55 per million doses). This study suggests that the JEV-L has a reasonable safety profile, most adverse events are relatively mild, with relatively rare neurologic events being observed.